Page last updated: 2024-08-26

nicotine and naltrexone

nicotine has been researched along with naltrexone in 86 studies

Research

Studies (86)

Timeframe	Studies, this research(%)	All Research%
pre-1990	5 (5.81)	18.7374
1990's	17 (19.77)	18.2507
2000's	39 (45.35)	29.6817
2010's	21 (24.42)	24.3611
2020's	4 (4.65)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Jolivette, LJ; Ward, KW	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Maneckjee, R; Minna, JD	1
Hamann, SR; Martin, WR	1
Abood, LG; Hashmi, M; Lerner-Marmarosh, N; Manda, S	1
Flores, CM; Hornby, PJ; Hulihan-Giblin, BA; Kellar, KJ; Lumpkin, MD	1
Coen, KM; Corrigall, WA	1
Davenport, KE; Houdi, AA; Van Loon, GR	1
Bostwick, M; Martin, WR; Sloan, JW	1
Flores, CM; Hulihan-Giblin, BA; Kellar, KJ	1
Coen, KM; Corrigall, WA; Herling, S	1
Chee, O; Keil, LC; Rosella-Dampman, LM; Summy-Long, JY	1
Kamerling, SG; Martin, WR; Sloan, JW; Su, TP; Wettstein, JG	1
Burden, HW; Davenport, A; Hodson, CA; Price, G	1
Feyerabend, C; Russell, MA; Stapleton, JA; Sutherland, G	1
Heidbreder, C; Shippenberg, TS; Shoaib, M	1
Burden, HW; Davis, MC; Hodson, CA	1
Caggiula, AR; Di Pirro, JM; Kristal, MB; Robinson-Vanderwerf, TM	1
Dhatt, R; Tejwani, GA; Wewers, ME	1
Bayer, BM; Mellon, RD	1
Colby, SM; Gnys, M; Hutchison, KE; Monti, PM; Niaura, RS; Rohsenow, DJ; Sirota, AD; Swift, RM	1
Behm, FM; Brauer, LH; Patel, P; Rose, JE; Westman, EC	1
Cheng, CH; Naylor, RJ; Ngan, MP; Rudd, JA; Wai, MK	1
Croghan, GA; Croghan, IT; Hurt, RD; Offord, KP; Wolter, TD; Wong, GY	1
King, AC; Meyer, PJ	1
Albuquerque, EX; Alkondon, M; Almeida, LE; Fawcett, WP; Pereira, EF; Randall, WR	1
Hahn, B; Shoaib, M; Stolerman, IP	1
Dermitzaki, E; Gravanis, A; Margioris, AN; Stournaras, C; Venihaki, M	1
Benowitz, NL; Levine, JD; Miao, FJ	1
Ahmadi, J; Ahmadi, M; Ahmadi, N; Ashkani, H	1
Krishnan-Sarin, S; Meandzija, B; O'Malley, S	1
Albuquerque, EX; Almeida, LE; Camara, AL; Maelicke, A; Pereira, EF	1
Kosten, TR; Sofuoglu, M	1
Hagan, JJ; Heidbreder, CA	1
Jepson, C; Lerman, C; Lynch, KG; Patterson, F; Perkins, K; Rukstalis, M; Strasser, A	1
Aso, E; Balerio, GN; Maldonado, R	1
Byars, JA; Frost-Pineda, K; Gold, MS; Jacobs, WS	1
Guaza, C; Llorente, R; Marco, EM; Moreno, E; Pérez-Alvarez, L; Viveros, MP	1
O'Brien, CP	1
Carstens, E; Carstens, MI; Cuellar, JM; Moore, JA; Pinkerton, KE; Simons, CT; Uyeminami, D	1
Cooney, NL; McKee, SA; O'Malley, SS; Toll, BA	1
Beilby, JJ; Doran, CM; Duszynski, KM; Mattick, RP	1
Blakeslee, A; Cooney, JL; Cooney, NL; Dubin, JA; Jatlow, P; Krishnan-Sarin, S; Makuch, R; McKee, SA; Meandzija, B; O'Malley, SS; Romano-Dahlgard, D; Wu, R	1
Berrettini, WH; Jepson, C; Lerman, C; Lynch, KG; O'Malley, S; Patterson, F; Perkins, K; Ray, R; Rukstalis, M; Strasser, A	1
Diehl, A; Mann, K	1
Hutchison, KE; Kaplan, GB; MacKinnon, SV; Monti, PM; Rohsenow, DJ; Sirota, AD; Swift, RM	1
Baskett, JA; Kracke, GR; Lever, JR; Miller, DK; Rodvelt, KR; Will, MJ	1
Jatlow, P; Martin, DJ; McKee, SA; O'Malley, SS; Toll, BA	1
Campbell, VC; Taylor, RE; Tizabi, Y	1
Katulak, NA; O'Malley, S; Toll, BA; Williams-Piehota, P	1
Blendy, J; Jepson, C; Lerman, C; Patterson, F; Perkins, K; Ray, R; Rukstalis, M; Strasser, AA; Wileyto, P	1
Fisher, DJ; Knott, VJ	1
Ahtee, L; Korpi, ER; Piltonen, M; Tuominen, RK; Vihavainen, T	1
Epstein, A; King, A; Munisamy, G; Walsh, Z	1
Cooney, JL; Cooney, NL; McKee, SA; O'Malley, SS; Toll, BA	1
al'Absi, M; Hatsukami, D; Westra, R; Wittmers, LE	1
Booth, S; Caggiula, AR; Donny, EC; Gharib, M; Liu, X; Palmatier, MI; Sved, AF	1
McKee, SA	1
Berrendero, F; Maldonado, R; Martín-García, E; Robledo, P; Trigo, JM	1
Ismayilova, N; Shoaib, M	1
Brown, ML; Kellar, KJ; Levin, ED; Li, TK; Lumeng, L; McDowell, BE; Paige, MA; Petro, A; Rezvani, AH; Rose, JE; Slade, S; Wells, C; Xiao, Y	1
Jatlow, P; Makuch, R; Meandzija, B; O'Malley, SS; Toll, BA; White, M; Wu, R	1
Amin, Z; Czarkowski, KA; Epperson, CN; Jatlow, P; Mazure, CM; O'Malley, SS; Toll, B; Wu, R	1
Carroll, FI; Damaj, MI; Jackson, KJ; McLaughlin, JP	1
Natividad, LA; O'Dell, LE; Orfila, JE; Tejeda, HA; Torres, OV	1
Chavkin, C; Chavkin, NW; Gustin, RM; Hagan, CE; Lemos, JC; Messinger, DI; Neumaier, JF; Schattauer, SS; Schindler, AG; Shankar, H; Smith, JS	1
Gillman, AG; Kosobud, AE; Leffel, JK; Timberlake, W	1
Coen, K; Funk, D; Grella, SL; Lê, AD; Li, Z	1
Coen, K; Funk, D; Lê, AD; Lo, S	1
Jatlow, PI; Mayne, ST; O'Malley, SS; Wu, R	1
Fisher, DC; Fletcher, PJ; Guy, EG; Higgins, GA	1
Goutier, W; Kloeze, M; McCreary, AC	1
Bruchas, MR; Carlezon, WA; Hourguettes, NJ; Nygard, SK; Sobczak, GG	1
D'Souza, MS; Norman, H; Ward, M	1
Anton, RF; Book, SW; Hoffman, M; Latham, PK; Randall, PK; Schacht, JP; Voronin, KE	1
Bardo, MT; Bell, RL; Crooks, PA; Dwoskin, LP; Maggio, SE; Nixon, K; Prendergast, MA; Saunders, MA; Zheng, G	1
Hauser, SR; Knight, CP; McBride, WJ; Pratt, LA; Rodd, ZA; Waeiss, RA	1
Bardo, MT; Chandler, CM; Maggio, SE; Nixon, K; Peng, H	1
Amstislavskaya, TG; de Abreu, MS; Demin, KA; Galstyan, DS; Giacomini, ACVV; Kalueff, AV; Kolesnikova, TO; Petersen, EV; Strekalova, T; Zabegalov, KN	1
al'Absi, M; Allen, S; Anker, JJ; Nakajima, M; Raatz, S	1
Bower, M; de Wit, H; Hoots, JK; Nunez, C; Schepers, ST; Wardle, MC	1

Reviews

7 review(s) available for nicotine and naltrexone

Article	Year
Pharmacologic management of relapse prevention in addictive disorders. The Psychiatric clinics of North America, 2004, Volume: 27, Issue:4 Topics: Administration, Cutaneous; Administration, Oral; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Disulfiram; Humans; Naltrexone; Narcotics; Nicotine; Smoking Cessation; Smoking Prevention; Substance-Related Disorders	2004
Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving. Current opinion in pharmacology, 2005, Volume: 5, Issue:1 Topics: Alcoholism; Clinical Trials as Topic; Cocaine-Related Disorders; Humans; Naltrexone; Narcotic Antagonists; Nicotine; Opioid-Related Disorders; Structure-Activity Relationship; Substance-Related Disorders; Tobacco Use Disorder	2005
Anticraving medications for relapse prevention: a possible new class of psychoactive medications. The American journal of psychiatry, 2005, Volume: 162, Issue:8 Topics: Alcoholism; Behavior, Addictive; Bupropion; Cocaine-Related Disorders; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Psychotropic Drugs; Secondary Prevention; Substance-Related Disorders; Tobacco Use Disorder	2005
[Pharmacological relapse prevention in alcohol and tobacco dependence]. Der Internist, 2007, Volume: 48, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Taurine; Tobacco Use Disorder	2007
Developing human laboratory models of smoking lapse behavior for medication screening. Addiction biology, 2009, Volume: 14, Issue:1 Topics: Alcohol Drinking; Arousal; Bupropion; Cues; Drug Evaluation, Preclinical; Humans; Models, Psychological; Motivation; Naltrexone; Nicotine; Psychotropic Drugs; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Social Facilitation; Tobacco Use Disorder	2009
Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neuroscience and biobehavioral reviews, 2010, Volume: 35, Issue:2 Topics: Animals; Behavior, Addictive; Humans; Motivation; Naltrexone; Neurotransmitter Agents; Nicotine; Opioid Peptides; Receptors, Nicotinic; Reinforcement, Psychology; Reward; Smoking Cessation; Tobacco Use Disorder	2010
Unconventional anxiety pharmacology in zebrafish: Drugs beyond traditional anxiogenic and anxiolytic spectra. Pharmacology, biochemistry, and behavior, 2021, Volume: 207 Topics: Animals; Anti-Anxiety Agents; Anxiety; Aspirin; Behavior, Animal; Disease Models, Animal; Humans; Lysergic Acid Diethylamide; Motor Activity; Naloxone; Naltrexone; Nicotine; Zebrafish	2021

Trials

22 trial(s) available for nicotine and naltrexone

Article	Year
Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology, 1995, Volume: 120, Issue:4 Topics: Adult; Affect; Behavior; Female; Humans; Male; Naltrexone; Nicotine; Placebo Effect; Reinforcement, Psychology; Smoking; Substance Withdrawal Syndrome; Time Factors	1995
Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology, 1998, Volume: 140, Issue:2 Topics: Adult; Affect; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Nicotine; Reinforcement, Psychology; Smoking; Substance Withdrawal Syndrome	1998
Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology, 1999, Volume: 142, Issue:2 Topics: Adult; Analysis of Variance; Cues; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Nicotine; Smoking; Substance Withdrawal Syndrome	1999
Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology, 1999, Volume: 143, Issue:4 Topics: Adult; Affect; Analysis of Variance; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Placebos; Smoking; Substance Withdrawal Syndrome; Surveys and Questionnaires	1999
A randomized trial of naltrexone for smoking cessation. Addiction (Abingdon, England), 1999, Volume: 94, Issue:8 Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Smoking Cessation	1999
Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacology, biochemistry, and behavior, 2000, Volume: 66, Issue:3 Topics: Adult; Affect; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder	2000
Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. Journal of substance abuse treatment, 2003, Volume: 24, Issue:3 Topics: Adult; Antihypertensive Agents; Chewing Gum; Clonidine; Double-Blind Method; Humans; Iran; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Prospective Studies; Smoking; Smoking Cessation; Smoking Prevention; Time Factors	2003
Naltrexone and nicotine patch smoking cessation: a preliminary study. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2003, Volume: 5, Issue:6 Topics: Administration, Cutaneous; Adult; Female; Ganglionic Stimulants; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Placebos; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome	2003
Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology, 2005, Volume: 180, Issue:1 Topics: Adolescent; Adult; Aged; Bupropion; Choice Behavior; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Reinforcement, Psychology; Smoking Cessation; Tobacco Use Disorder	2005
Naltrexone augments the effects of nicotine replacement therapy in female smokers. Journal of addictive diseases, 2005, Volume: 24, Issue:2 Topics: Administration, Cutaneous; Administration, Topical; Adult; Combined Modality Therapy; Double-Blind Method; Female; Humans; Naltrexone; Narcotic Antagonists; Nicotine; Psychotherapy; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder	2005
Do daily interactive voice response reports of smoking behavior correspond with retrospective reports? Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 2005, Volume: 19, Issue:3 Topics: Data Collection; Double-Blind Method; Female; Humans; Male; Mental Recall; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Patient Compliance; Self Disclosure; Sensitivity and Specificity; Smoking; Smoking Cessation; Telephone; Time Factors	2005
A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Archives of internal medicine, 2006, Mar-27, Volume: 166, Issue:6 Topics: Administration, Cutaneous; Administration, Oral; Ambulatory Care; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Treatment Outcome; Weight Gain	2006
Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology, 2006, Volume: 188, Issue:3 Topics: Adaptation, Psychological; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Polymorphism, Genetic; Receptors, Opioid, mu; Reinforcement, Psychology; Risk Factors; Sex Factors; Smoking; Smoking Cessation; Substance Withdrawal Syndrome	2006
High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Experimental and clinical psychopharmacology, 2007, Volume: 15, Issue:1 Topics: Administration, Cutaneous; Administration, Oral; Adult; Blood Pressure; Breath Tests; Capsules; Carbon Monoxide; Demography; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Smoking; Substance Withdrawal Syndrome; Surveys and Questionnaires; Tablets	2007
Validation of a scale for the assessment of food cravings among smokers. Appetite, 2008, Volume: 50, Issue:1 Topics: Administration, Cutaneous; Appetite; Dietary Fats; Dietary Sucrose; Female; Food Preferences; Humans; Male; Naltrexone; Nicotine; Placebos; Reproducibility of Results; Smoking; Smoking Cessation; Surveys and Questionnaires; Taste; Weight Gain	2008
Naltrexone alteration of the nicotine-induced EEG and mood activation response in tobacco-deprived cigarette smokers. Experimental and clinical psychopharmacology, 2007, Volume: 15, Issue:4 Topics: Adult; Affect; Analysis of Variance; Blood Pressure; Double-Blind Method; Electroencephalography; Female; Heart Rate; Humans; Male; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Substance Withdrawal Syndrome; Surveys and Questionnaires	2007
The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. Journal of addictive diseases, 2008, Volume: 27, Issue:1 Topics: Administration, Cutaneous; Adult; Combined Modality Therapy; Counseling; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Personality Inventory; Smoking Cessation; Treatment Outcome	2008
Blunted opiate modulation of hypothalamic-pituitary-adrenocortical activity in men and women who smoke. Psychosomatic medicine, 2008, Volume: 70, Issue:8 Topics: Adrenocorticotropic Hormone; Arousal; Double-Blind Method; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Naltrexone; Narcotic Antagonists; Nicotine; Opioid Peptides; Pain Measurement; Pain Threshold; Pituitary-Adrenal System; Saliva; Sex Factors; Thermosensing; Tobacco Use Disorder; Young Adult	2008
Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. Drug and alcohol dependence, 2010, Oct-01, Volume: 111, Issue:3 Topics: Administration, Cutaneous; Adult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Nicotine; Prospective Studies; Smoking; Smoking Cessation; Weight Gain	2010
Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug and alcohol dependence, 2010, Nov-01, Volume: 112, Issue:1-2 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Body Weight; Female; Humans; Interviews as Topic; Male; Medication Adherence; Menstrual Cycle; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Sex Characteristics; Smoking Cessation; Treatment Outcome; Young Adult	2010
Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2014, Volume: 16, Issue:8 Topics: Administration, Cutaneous; Adult; Antioxidants; Bilirubin; Cardiovascular Diseases; Counseling; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Naltrexone; Nicotine; Risk Factors; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Treatment Outcome	2014
Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. Alcoholism, clinical and experimental research, 2018, Volume: 42, Issue:4 Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Biomarkers; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Naltrexone; Nicotine; Sialoglycoproteins; Smoking; Transferrin; Treatment Outcome; Young Adult	2018

Other Studies

57 other study(ies) available for nicotine and naltrexone

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. Journal of pharmaceutical sciences, 2005, Volume: 94, Issue:7 Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution	2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19 Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Nonconventional opioid binding sites mediate growth inhibitory effects of methadone on human lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 1992, Feb-15, Volume: 89, Issue:4 Topics: Binding Sites; Calcium; Cell Death; Cell Division; Cell Membrane; Cyclic AMP; Cycloheximide; Dactinomycin; Growth Inhibitors; Humans; Methadone; Morphine; Naltrexone; Nicotine; Pertussis Toxin; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Stereoisomerism; Tumor Cells, Cultured; Virulence Factors, Bordetella	1992
Opioid and nicotinic analgesic and hyperalgesic loci in the rat brain stem. The Journal of pharmacology and experimental therapeutics, 1992, Volume: 261, Issue:2 Topics: Analgesia; Animals; Brain Stem; Dose-Response Relationship, Drug; Ethylketocyclazocine; Female; Mecamylamine; Microinjections; Naltrexone; Nicotine; Rats; Rats, Inbred Strains; Receptors, Opioid	1992
Opioid receptor antagonist affinity ligands: 6 beta-bromoacetamido-6-desoxynaltrexone and 6 beta-thioglycolamido-6-desoxynaltrexone. Neurochemical research, 1992, Volume: 17, Issue:12 Topics: Affinity Labels; Analgesia; Animals; Brain; Cattle; Cell Membrane; Hydrogen-Ion Concentration; Kinetics; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Nicotine; Quinuclidinyl Benzilate; Receptors, Opioid	1992
Partial characterization of a neurotransmitter pathway regulating the in vivo release of prolactin. Neuroendocrinology, 1992, Volume: 55, Issue:5 Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Bromocriptine; Haloperidol; Male; Mecamylamine; Methysergide; Morphine; Naltrexone; Narcotic Antagonists; Neurotransmitter Agents; Nicotine; Nicotinic Antagonists; Pituitary Gland; Prolactin; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Nicotinic; Receptors, Opioid; Receptors, Serotonin; Serotonin Antagonists; Tetrahydronaphthalenes	1992
Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology, 1991, Volume: 104, Issue:2 Topics: Animals; Cocaine; Conditioning, Operant; Male; Naloxone; Naltrexone; Narcotic Antagonists; Nicotine; Rats; Reinforcement Schedule; Self Administration	1991
Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neuroscience letters, 1990, May-18, Volume: 113, Issue:1 Topics: Analgesia; Animals; Brain; Endorphins; Injections, Intraventricular; Male; Morphine; Naltrexone; Nicotine; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, mu	1990
Mechanisms involved in the respiratory depressant actions of nicotine in anesthetized rats. Pharmacology, biochemistry, and behavior, 1989, Volume: 34, Issue:3 Topics: Anesthesia; Animals; Female; Hexamethonium; Hexamethonium Compounds; Mecamylamine; Naltrexone; Nicotine; Pentobarbital; Rats; Rats, Inbred Strains; Receptors, Nicotinic; Receptors, Opioid; Respiration; Urethane	1989
Naltrexone blocks nicotine-induced prolactin release. Neuropharmacology, 1989, Volume: 28, Issue:11 Topics: Animals; Catheterization; Male; Mecamylamine; Morphine; Naltrexone; Nicotine; Prolactin; Rats; Rats, Inbred Strains	1989
Evidence for opioid mechanisms in the behavioral effects of nicotine. Psychopharmacology, 1988, Volume: 96, Issue:1 Topics: Animals; Behavior, Animal; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Heroin; Male; Mecamylamine; Naltrexone; Nicotine; Rats; Rats, Inbred Strains; Receptors, Opioid	1988
Naltrexone effects on plasma vasopressin concentration elevated and lowered by various stimuli. The Journal of pharmacology and experimental therapeutics, 1983, Volume: 226, Issue:2 Topics: Animals; Arginine Vasopressin; Blood Pressure; Hematocrit; Male; Naloxone; Naltrexone; Nicotine; Rats; Rats, Inbred Strains; Sodium; Stress, Physiological; Water-Electrolyte Balance	1983
Interaction between nicotine and endogenous opioid mechanisms in the unanesthetized dog. Pharmacology, biochemistry, and behavior, 1982, Volume: 17, Issue:4 Topics: Animals; Body Temperature; Brain; Dogs; Endorphins; Enkephalin, Methionine; Female; Heart Rate; Injections, Intraventricular; Naltrexone; Nicotine; Pupil; Reflex; Respiration; Skin Physiological Phenomena	1982
Naltrexone treatment attenuates the inhibitory effect of nicotine treatment on serum LH in rats. Life sciences, 1993, Volume: 53, Issue:10 Topics: Adrenalectomy; Animals; Dexamethasone; Drug Therapy, Combination; Luteinizing Hormone; Male; Naltrexone; Nicotine; Rats; Rats, Sprague-Dawley	1993
Differential role of delta-opioid receptors in the development and expression of behavioral sensitization to cocaine. European journal of pharmacology, 1996, Mar-18, Volume: 298, Issue:3 Topics: Animals; Behavior, Animal; Cocaine; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Narcotics; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta	1996
Effect of prior nicotine treatment on drug induced changes in serum LH concentrations in rats. Life sciences, 1997, Volume: 60, Issue:25 Topics: Adrenergic alpha-Agonists; Animals; Clonidine; Dopamine Antagonists; Drug Administration Schedule; Drug Interactions; Gonadotropin-Releasing Hormone; Haloperidol; Luteinizing Hormone; Male; Naloxone; Naltrexone; Narcotic Antagonists; Neurotransmitter Agents; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Stimulation, Chemical	1997
The analgesia-enhancing component of ingested amniotic fluid does not affect nicotine-induced antinociception in naltrexone-treated rats. Pharmacology, biochemistry, and behavior, 1997, Volume: 58, Issue:1 Topics: Amniotic Fluid; Analgesia; Analgesics; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Female; Morphine; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Pain Measurement; Pregnancy; Rats; Reaction Time	1997
The effects of morphine, nicotine and epibatidine on lymphocyte activity and hypothalamic-pituitary-adrenal axis responses. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 288, Issue:2 Topics: Adjuvants, Immunologic; Analgesics, Opioid; Animals; Bridged Bicyclo Compounds, Heterocyclic; Chlorisondamine; Dose-Response Relationship, Drug; Drug Interactions; Hypothalamo-Hypophyseal System; Lymphocyte Activation; Male; Morphine; Naltrexone; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Pituitary-Adrenal System; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Receptors, Opioid; T-Lymphocytes	1999
Modulation of emesis by fentanyl and opioid receptor antagonists in Suncus murinus (house musk shrew). European journal of pharmacology, 1999, Jun-11, Volume: 374, Issue:1 Topics: Animals; Antiemetics; Female; Fentanyl; Male; Naloxone; Naltrexone; Narcotic Antagonists; Nicotine; Receptors, Opioid; Shrews; Vomiting	1999
The opioid antagonist naltrexone inhibits activity and alters expression of alpha7 and alpha4beta2 nicotinic receptors in hippocampal neurons: implications for smoking cessation programs. Neuropharmacology, 2000, Volume: 39, Issue:13 Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Cells, Cultured; Electrophysiology; Female; Hippocampus; In Vitro Techniques; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Patch-Clamp Techniques; Pregnancy; Rats; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Smoking Cessation; Up-Regulation	2000
Kappa-opioid receptor modulation of nicotine-induced behaviour. Neuropharmacology, 2000, Volume: 39, Issue:13 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Behavior, Animal; Benzeneacetamides; Benzofurans; Dose-Response Relationship, Drug; Injections, Intraventricular; Male; Motor Activity; Naltrexone; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats; Receptors, Opioid, kappa	2000
Opioids suppress basal and nicotine-induced catecholamine secretion via a stabilizing effect on actin filaments. Endocrinology, 2001, Volume: 142, Issue:5 Topics: Actins; Animals; Benzeneacetamides; Cytochalasin B; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine-2-Alanine; Humans; Naltrexone; Narcotics; Nicotine; Norepinephrine; PC12 Cells; Pyrrolidines; Rats	2001
Endogenous opioids suppress activation of nociceptors by sub-nanomolar nicotine. British journal of pharmacology, 2001, Volume: 133, Issue:1 Topics: Adrenal Medulla; Analysis of Variance; Animals; Animals, Newborn; Bradykinin; Capsaicin; Dose-Response Relationship, Drug; Hexamethonium; Inflammation; Knee Joint; Male; Naloxone; Naltrexone; Narcotic Antagonists; Neurokinin-1 Receptor Antagonists; Neurons, Afferent; Nicotine; Nociceptors; Opioid Peptides; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Receptors, Opioid; Sciatic Nerve; Time Factors	2001
Sensitivity of neuronal nicotinic acetylcholine receptors to the opiate antagonists naltrexone and naloxone: receptor blockade and up-regulation. Bioorganic & medicinal chemistry letters, 2004, Apr-19, Volume: 14, Issue:8 Topics: Cell Line; Gene Expression; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Nicotine; Patch-Clamp Techniques; Receptors, Nicotinic; Sensitivity and Specificity; Smoking Cessation; Structure-Activity Relationship; Time Factors; Up-Regulation	2004
Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology, 2005, Volume: 181, Issue:2 Topics: Analysis of Variance; Animals; Anxiety Disorders; Behavior, Animal; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Maze Learning; Mecamylamine; Mice; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Receptors, Opioid	2005
The kappa-opioid receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety. Behavioural brain research, 2005, Sep-08, Volume: 163, Issue:2 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Anxiety; Behavior, Animal; Corticosterone; Drug Interactions; Endocrine System; Male; Maze Learning; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Radioimmunoassay; Rats; Rats, Wistar; Receptors, Opioid, kappa	2005
Nicotinic receptor involvement in antinociception induced by exposure to cigarette smoke. Neuroscience letters, 2005, Dec-02, Volume: 389, Issue:2 Topics: Analgesics; Animals; Dose-Response Relationship, Drug; Drug Tolerance; Male; Mecamylamine; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Nociceptors; Pain; Pain Threshold; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Receptors, Opioid, mu; Smoking	2005
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice. Addictive behaviors, 2006, Volume: 31, Issue:11 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Female; Health Care Surveys; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Substance-Related Disorders; Taurine; Tobacco Use Disorder	2006
Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. Drug and alcohol dependence, 2007, Jul-10, Volume: 89, Issue:2-3 Topics: Analgesics, Opioid; Animals; Binding, Competitive; Brain; Dopamine; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Guinea Pigs; In Vitro Techniques; Lobeline; Mecamylamine; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Nicotine; Oocytes; Radioligand Assay; Receptors, Opioid; Receptors, Opioid, mu; Xenopus laevis	2007
Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2007, Volume: 9, Issue:5 Topics: Adult; Attitude to Health; Factor Analysis, Statistical; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Nicotine; Patient Compliance; Psychometrics; Reproducibility of Results; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Tobacco Use Disorder	2007
Effects of selective opioid receptor antagonists on alcohol-induced and nicotine-induced antinociception. Alcoholism, clinical and experimental research, 2007, Volume: 31, Issue:8 Topics: Analgesics; Animals; Central Nervous System Depressants; Ethanol; Hot Temperature; Male; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Pain Measurement; Peptide Fragments; Peptides; Rats; Rats, Wistar; Reaction Time; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Somatostatin	2007
CREB1 haplotypes and the relative reinforcing value of nicotine. Molecular psychiatry, 2007, Volume: 12, Issue:7 Topics: Association Learning; Case-Control Studies; Choice Behavior; Cyclic AMP Response Element-Binding Protein; Double-Blind Method; Haplotypes; Humans; Linkage Disequilibrium; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; Regression Analysis; Reward; Smoking; Tobacco Use Disorder	2007
Morphine-nicotine interaction in conditioned place preference in mice after chronic nicotine exposure. European journal of pharmacology, 2008, Jun-10, Volume: 587, Issue:1-3 Topics: Analgesics, Opioid; Animals; Autoradiography; Conditioning, Operant; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Guanosine 5'-O-(3-Thiotriphosphate); Male; Mice; Morphine; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Receptors, Opioid, mu	2008
Correspondence of Interactive Voice Response (IVR) reports of nicotine withdrawal, craving, and negative mood with questionnaire ratings. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2008, Volume: 10, Issue:6 Topics: Adult; Comorbidity; Depression; Female; Humans; Irritable Mood; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Self Disclosure; Self-Assessment; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires	2008
Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats. Psychopharmacology, 2009, Volume: 202, Issue:4 Topics: Animals; Conditioning, Operant; Cues; Dose-Response Relationship, Drug; Extinction, Psychological; Food; Male; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Self Administration	2009
Alteration of intravenous nicotine self-administration by opioid receptor agonist and antagonists in rats. Psychopharmacology, 2010, Volume: 210, Issue:2 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Dose-Response Relationship, Drug; Feeding Behavior; Male; Naloxone; Naltrexone; Narcotic Antagonists; Nicotine; Rats; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Self Administration; Tobacco Use Disorder	2010
Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. Psychopharmacology, 2010, Volume: 211, Issue:2 Topics: Animals; Azetidines; Dose-Response Relationship, Drug; Drug Administration Schedule; Ethanol; Male; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Pyridines; Rats; Receptors, Nicotinic; Reward; Saccharin; Self Administration	2010
Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice. Psychopharmacology, 2013, Volume: 226, Issue:4 Topics: Animals; Conditioning, Psychological; Disease Models, Animal; Extinction, Psychological; Male; Mice; Mice, Inbred ICR; Naltrexone; Narcotic Antagonists; Nicotine; Receptors, Opioid, kappa; Recurrence; Risk Factors; Self Administration; Smoking; Stress, Psychological	2013
Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner. Psychopharmacology, 2012, Volume: 224, Issue:2 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Aging; Animals; Behavior, Animal; Dopamine; Dose-Response Relationship, Drug; Male; Naltrexone; Nicotine; Nucleus Accumbens; Rats; Rats, Wistar; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Tobacco Use Disorder	2012
Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Dec-05, Volume: 32, Issue:49 Topics: Animals; Avoidance Learning; Brain; Cocaine; Corpus Striatum; Dopamine; Dynorphins; G-Protein-Coupled Receptor Kinase 3; Male; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microinjections; Naltrexone; Narcotic Antagonists; Nicotine; Nucleus Accumbens; p38 Mitogen-Activated Protein Kinases; Raphe Nuclei; Receptors, Opioid, kappa; Reward; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction; Stress, Psychological; Substance Withdrawal Syndrome; Synaptosomes	2012
Behavioral characteristics and pharmacological manipulations of a nicotine-entrainable circadian oscillator. Chronobiology international, 2013, Volume: 30, Issue:7 Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Behavior, Animal; Benzoxazoles; Circadian Rhythm; Feeding Behavior; Female; Fructose; Light; Motor Activity; Naltrexone; Naphthyridines; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Oscillometry; Rats; Rats, Sprague-Dawley; Time Factors; Topiramate; Urea	2013
Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats. Behavioural brain research, 2014, May-15, Volume: 265 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic alpha-2 Receptor Antagonists; Analgesics, Non-Narcotic; Animals; Conditioning, Operant; Drug Administration Schedule; Drug Interactions; Extinction, Psychological; Male; Naltrexone; Nicotine; Nicotinic Agonists; Rats; Rats, Long-Evans; Receptors, Opioid, kappa; Self Administration; Stress, Psychological; Tobacco Use Disorder; Yohimbine	2014
Operant self-administration of alcohol and nicotine in a preclinical model of co-abuse. Psychopharmacology, 2014, Volume: 231, Issue:20 Topics: Alcoholism; Animals; Behavior, Addictive; Conditioning, Operant; Disease Models, Animal; Ethanol; Male; Naltrexone; Nicotine; Rats; Rats, Long-Evans; Self Administration; Smoking	2014
Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats. Behavioural pharmacology, 2014, Volume: 25, Issue:8 Topics: Animals; Benzazepines; Bupropion; Cholinergic Agents; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Male; Naltrexone; Narcotic Antagonists; Nicotine; Quinoxalines; Rats; Rats, Long-Evans; Reinforcement, Psychology; Varenicline	2014
Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids. Addiction biology, 2016, Volume: 21, Issue:2 Topics: Acamprosate; Analysis of Variance; Animals; Antidiuretic Hormone Receptor Antagonists; Bupropion; Dose-Response Relationship, Drug; Fructose; Indoles; Male; Motor Activity; Naltrexone; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats, Wistar; Taurine; Tobacco Use Cessation Devices; Topiramate	2016
Stress-Induced Reinstatement of Nicotine Preference Requires Dynorphin/Kappa Opioid Activity in the Basolateral Amygdala. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2016, 09-21, Volume: 36, Issue:38 Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Basolateral Nuclear Complex; Clozapine; Conditioning, Operant; Drug-Seeking Behavior; Dynorphins; Extinction, Psychological; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Proto-Oncogene Proteins c-fos; Receptors, Opioid, kappa; Reinforcement, Psychology; Yohimbine	2016
Effects of pharmacological manipulation of the kappa opioid receptors on the aversive effects of nicotine. Behavioural brain research, 2018, 02-15, Volume: 338 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Avoidance Learning; Conditioning, Operant; Male; Naltrexone; Narcotic Antagonists; Nicotine; Rats; Rats, Wistar; Receptors, Opioid, kappa; Taste	2018
An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI. Drug and alcohol dependence, 2018, 12-01, Volume: 193 Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Disease Models, Animal; Ethanol; Female; Naltrexone; Nicotine; Nicotinic Antagonists; Picolines; Pyridinium Compounds; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Treatment Outcome; Varenicline	2018
Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats. Psychopharmacology, 2019, Volume: 236, Issue:6 Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Injections, Subcutaneous; Naltrexone; Nicotine; Random Allocation; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline	2019
Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats. Drug and alcohol dependence, 2020, 07-01, Volume: 212 Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Male; Naltrexone; Nicotine; Rats; Rats, Sprague-Dawley; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline	2020
Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system. Drug and alcohol dependence, 2021, 08-01, Volume: 225 Topics: Analgesics, Opioid; Eating; Humans; Naltrexone; Nicotiana; Nicotine; Substance Withdrawal Syndrome	2021
Pharmacological investigations of effort-based decision-making in humans: Naltrexone and nicotine. PloS one, 2022, Volume: 17, Issue:10 Topics: Adult; Cholinergic Agents; Decision Making; Dopamine; Humans; Motivation; Naltrexone; Nicotine; Pilot Projects; Reward	2022